Silence Therapeutics Showcases Promising Phase 2 Results
Silence Therapeutics (SLN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Business Insider10h
Promising Phase II Results and Safety Profile Justify Buy Rating for Silence Therapeutics’ Zerlasiran
primarily revolving around promising clinical trial results for Silence Therapeutics’ lead product candidate, zerlasiran. The recent data from the ALPACAR-360 phase II study presented at the American ...
Amgen Sells Off: Keep Calm And Buy The Dip
Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...
Vaccinex, Inc.: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage bio ...